ArticleBMC biotechnology2026
A TXNIP-driven bioluminescent reporter for high-throughput discovery of glycolytic inhibitors against renal cell carcinoma.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The glycolytic inhibitor 2-deoxy-D-glucose (2-DG) has demonstrated consistent preclinical antitumor efficacy; however, the discovery of novel 2-DG-like agents for renal cell carcinoma (RCC) remains challenging due to the lack of specific, high-throughput screening (HTS) tools. In this study, RNA-seq analysis identified Thioredoxin-interacting protein (TXNIP) as a gene markedly upregulated by 2-DG in A498 RCC cells. We further confirmed that 2-DG transcriptionally upregulates the expression of both TXNIP and its transcription factor, MLX-interacting protein (MLXIP). Leveraging this mechanism, we engineered a bioluminescent reporter system by constructing a TXNIP promoter-driven luciferase construct (TXNIP-Pro-Luc2) and generating a stable A498-TXNIP-Pro-Luc2 cell line. In this system, 2-DG and its functional analogs activate the TXNIP promoter, resulting in a concentration-dependent increase in bioluminescence that serves as a direct functional readout for 2-DG-like activity. Collectively, we developed a novel reporter system based on the MLXIP/TXNIP pathway, which shows promise as a high-throughput screening platform for identifying glycolysis-targeting anti-RCC drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.